Pharmaceutical composition comprising prmt5 inhibitor and EGFR inhibitor
Patent Information
- Application Number
- HK62026125265
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-04
- Filing Date
- 2026-06-25
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580003272.3 (22) Application Date 2025.01.24 (66) Domestic Priority Data 202410116672.2 2024.01.26 CN 202410245514.7 2024.03.04 CN (85) PCT International Application Entering National Phase Date 2025.12.18 (86) PCT International Application Application Data PCT / CN2025 / 074945 2025.01.24 (87) PCT International Application Publication Data WO2025 / 157287 ZH 2025.07.31 (71) Applicant Shanghai Pailong Biotechnology Co., Ltd. Address 201210 Pudong New Area, Shanghai, China (Shanghai) Room C101, Building 1, No. 1976, Gaoke Middle Road, Free Trade Zone (72) Inventors: Mao Weifeng, Yao Bing, Fred Julian Aswad, Li Mingxi, Gu Xiaohui, James David Joseph (74) Patent Agency: Beijing Shengran Weian Intellectual Property Agency (General Partnership) 16297 Patent Attorney: Wang Hong (51) Int.Cl. A61K 45 / 06 (2006.01) A61K 31 / 536 (2006.01) A61K 31 / 519 (2006.01) A61P 35 / 00 (2006.01) A61K 31 / 501 (2006.01) A61K 31 / 4985 (2006.01) (54) Pharmaceutical Composition with Title Containing PRMT5 Inhibitor and EGFR Inhibitor (57) Abstract discloses a pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. This pharmaceutical composition can be used to treat a variety of cancers, including solid tumors. This combination product can be used to treat any number of diseases associated with PRMT5 and / or EGFR. CN 121398850 A 2026.01.23 CN 1 21 39 88 50 A
